Literature DB >> 19751260

The West Midlands Bladder Cancer Prognosis Programme: rationale and design.

Maurice P Zeegers1, Richard T Bryan, Carolyn Langford, Lucinda Billingham, Paul Murray, Neeta S Deshmukh, Syed Hussain, Nick James, D Michael A Wallace, K K Cheng.   

Abstract

OBJECTIVE To describe the rationale and design of the Bladder Cancer Prognosis Programme (BCPP), and to demonstrate the capability of this design. METHODS There is a need to understand the determinants of bladder cancer to help reduce recurrence, progression, morbidity, mortality and related costs. We previously showed that lifestyle factors are important for determining the risk of bladder cancer, but little is known about their importance in determining the risk of recurrence or progression after diagnosis. Also, histopathological factors alone provide only crude prognostication; the analysis of molecular markers represents a method for refinement but research in this area has not been useful in informing therapeutic decisions or prognostication. The BCPP is a prospective longitudinal cohort study of all patients with newly diagnosed bladder cancer within the West Midlands (UK), investigating the influence of lifestyle factors on recurrence and progression, health-related quality of life, the predictive effect of a panel of molecular markers on recurrence or progression, and the establishment of Europe's largest comprehensive bladder cancer bio-repository. It also incorporates the first randomized clinical trial on the efficacy of selenium and vitamin E on bladder cancer. The numbers and proportions of eligible patients recruited, questionnaires completed and specimens obtained were all recorded. RESULTS Since December 2005, 771 patients have been recruited (68% of eligible patients) and of these, 331 are currently being followed up by questionnaires. We have obtained blood, urine and tumour tissues from 92%, 80% and 80% of patients, respectively. CONCLUSIONS The design of the BCPP has allowed this study to be incorporated into routine clinical work throughout the West Midlands, achieving high levels of recruitment, and data and specimen collection. This might represent a model for the future investigation of urological and other malignancies.

Entities:  

Mesh:

Year:  2009        PMID: 19751260     DOI: 10.1111/j.1464-410X.2009.08849.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  31 in total

Review 1.  Selenium for preventing cancer.

Authors:  Marco Vinceti; Gabriele Dennert; Catherine M Crespi; Marcel Zwahlen; Maree Brinkman; Maurice P A Zeegers; Markus Horneber; Roberto D'Amico; Cinzia Del Giovane
Journal:  Cochrane Database Syst Rev       Date:  2014-03-30

2.  Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.

Authors:  Mark O Kitchen; Richard T Bryan; Richard D Emes; John R Glossop; Christopher Luscombe; K K Cheng; Maurice P Zeegers; Nicholas D James; Adam J Devall; Charles A Mein; Lyndon Gommersall; Anthony A Fryer; William E Farrell
Journal:  Epigenetics       Date:  2016-03-01       Impact factor: 4.528

3.  Mechanisms of recurrence of Ta/T1 bladder cancer.

Authors:  Richard T Bryan; Stuart I Collins; Mark C Daykin; Maurice P Zeegers; K K Cheng; D Michael A Wallace; Graham M Sole
Journal:  Ann R Coll Surg Engl       Date:  2010-06-01       Impact factor: 1.891

Review 4.  Selenium for preventing cancer.

Authors:  Gabriele Dennert; Marcel Zwahlen; Maree Brinkman; Marco Vinceti; Maurice P A Zeegers; Markus Horneber
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

Review 5.  Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena.

Authors:  Richard T Bryan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-02-05       Impact factor: 6.237

Review 6.  Emerging endoscopic and photodynamic techniques for bladder cancer detection and surveillance.

Authors:  Prashant Patel; Richard T Bryan; D Michael A Wallace
Journal:  ScientificWorldJournal       Date:  2011-12-29

7.  Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium.

Authors:  Maria E Goossens; Frank Buntinx; Steven Joniau; Koen Ackaert; Filip Ameye; Ignace Billiet; Johan Braeckman; Alex Breugelmans; Jochen Darras; Kurt Dilen; Lieven Goeman; Eliane Kellen; Bertrand Tombal; Siska Van Bruwaene; Ben Van Cleyenbreuge; Frank Van der Aa; Kris Vekemans; Hendrik Van Poppel; Maurice P Zeegers
Journal:  BMC Urol       Date:  2012-03-21       Impact factor: 2.264

8.  Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma.

Authors:  N J Shimwell; R T Bryan; W Wei; N D James; K K Cheng; M P Zeegers; P J Johnson; A Martin; D G Ward
Journal:  Br J Cancer       Date:  2013-04-16       Impact factor: 7.640

Review 9.  Selenium for preventing cancer.

Authors:  Marco Vinceti; Tommaso Filippini; Cinzia Del Giovane; Gabriele Dennert; Marcel Zwahlen; Maree Brinkman; Maurice Pa Zeegers; Markus Horneber; Roberto D'Amico; Catherine M Crespi
Journal:  Cochrane Database Syst Rev       Date:  2018-01-29

10.  Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.

Authors:  Mark O Kitchen; Richard T Bryan; Kim E Haworth; Richard D Emes; Christopher Luscombe; Lyndon Gommersall; K K Cheng; Maurice P Zeegers; Nicholas D James; Adam J Devall; Anthony A Fryer; William E Farrell
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.